Related Experiment Videos
[The budget control function of the Drug Reimbursement System]
M H Pronk1, G J Bonsel, A van der Kuy
1Academisch Medisch Centrum/Universiteit van Amsterdam, afd. Sociale Geneeskunde, Postbus 22.660, 1100 DD Amsterdam.
Nederlands Tijdschrift Voor Geneeskunde
|October 3, 2002
Summary
The Dutch Price Reference System (GVS) aimed to limit pharmaceutical cost growth but did not meet its budget goals. Despite this, the GVS likely influenced budget control and should continue.
Area of Science:
- Health Economics
- Pharmaceutical Policy
Context:
- The Dutch Price Reference System (GVS) was implemented to control pharmaceutical expenditure growth.
- The system's primary focus was budget control, not cost-effectiveness through substitution.
Purpose:
- To evaluate the effectiveness of the Dutch Price Reference System (GVS) over 10 years.
- To assess whether the GVS achieved its goal of reducing annual extramural pharmaceutical cost growth to 4.1%.
Summary:
- The GVS did not achieve its budget control targets, with actual growth rates significantly exceeding the 4.1% goal.
- Epidemiological and demographic factors account for approximately 3% of annual growth, leaving limited room for autonomous growth.
- The observed 8% annual growth indicates substantial autonomous growth, though lower than in some other European countries.
Impact:
- The GVS and associated measures likely exerted a significant budget-controlling influence, despite not meeting explicit targets.
- The current Dutch health policy aligns with the GVS framework, suggesting its continued relevance.
- The study recommends the continuation of the GVS, considering its role in influencing pharmaceutical cost management.